Fresenius Kabi AG has indicated that it is much more interested for now in gaining approval for a high-concentration formulation of its Idacio (adalimumab-aacf) biosimilar in the US over securing a proposed designation for interchangeability with its reference product Humira (adalimumab).
Speaking with investors as the Fresenius group presented its second-quarter financial results, Fresenius CEO Michael Sen answered “not yet” when asked if the company had given any thought to